

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets




(11) Publication number:

0 686 642 A2

(12)

EUROPEAN PATENT APPLICATION(21) Application number: **95108266.8**(22) Date of filing: **30.05.95**(51) Int. Cl.⁶: **C07K 5/06, C07K 5/08,
C07D 401/12, C07D 207/04,
C07D 211/06, A61K 38/55,
A61K 31/395**(30) Priority: **10.06.94 US 257995**(43) Date of publication of application:
13.12.95 Bulletin 95/50(64) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**(71) Applicant: **BRISTOL-MYERS SQUIBB
COMPANY
P.O. Box 4000
Princeton, NJ 08543-4000 (US)**(72) Inventor: **Kim, Kyoung S.
11 LePark Dr.
Lawrenceville, NJ 08648 (US)
Inventor: Kimball, Spencer D.
13 Charred Oak Lane
East Windsor, NJ 08520 (US)
Inventor: Das, Jagabandhu
38 Martin Lane
Mercerville, NJ 08619 (US)
Inventor: Iwanowicz, Edwin J.
30 Haverford Rd.
Cranbury, NJ 08512 (US)
Inventor: Han, Wen-Ching
2062 East Wellington Rd.
Newtown, PA 18940 (US)**(74) Representative: **Josif, Albert, Dr.-Ing. et al
Baaderstrasse 3
D-80469 München (DE)**(54) **Modified guanidino and amidino thrombin inhibitors**

(57) Thrombin inhibitors are provided which have the formula



wherein Z is a thrombin inhibitor substructure containing distal and proximal binding site residues;
and


R¹ is cyano, hydroxyl, alkoxy, amino, aminoalkyl or nitro.

EP 0 686 642 A2

The present invention relates to modified guanidino or modified amidino compounds which are thrombin inhibitors and thus useful in inhibiting formation of thrombin.

In accordance with the present invention, compounds having thrombin inhibitory activity are provided having the structure I


I.




wherein Z is a thrombin inhibitor substructure containing residues binding at the distal and proximal sites (as described by Banner and Hadvary, J. Biol. Chem. (1991), 266, 20085-20093); and

R¹ is cyano, hydroxyl, alkoxy, amino, aminoalkyl or nitro; including all stereoisomers thereof, and all pharmaceutically acceptable salts thereof.

It will be appreciated that the formula I structure includes all tautomers thereof, for example,




or




Examples of the Z thrombin inhibitor substructure include


(Z1)



(Z2)




(Z3)




Thus, the compounds of the invention include compounds of the structure


II



wherein G is an amido, sulfur or oxygen linking moiety including




including all stereoisomers thereof; and including all pharmaceutically acceptable salts thereof; wherein n is 0, 1 or 2; and the lower bond connects with




R² and R³ are independently hydrogen, lower alkyl, cycloalkyl, aryl, hydroxy, alkoxy, oxo, thioether, thioalkyl, thioaryl, amino or alkylamino; or R² and R³ together with the carbons to which they are attached form a cycloalkyl, aryl, or heteroaryl ring;

R⁴ is hydrogen, hydroxyalkyl, hydroxy(alkyl)alkyl, aminoalkyl, alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amidoalkyl, arylalkoxyalkyl, or an amino acid side chain, either protected or unprotected; and R⁵ is




where R⁶ is lower alkyl, aryl, arylalkyl, cycloheteroalkyl, heteroaryl, quinoliny or tetrahydroquinoliny; or R⁵ is hydrogen,



-CO₂R⁷ or -CONHR⁷ (wherein R⁷ is lower alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroaryl). R⁵ can also be R⁷O₂C-alkyl-,




or



(wherein R⁷ is H, alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroalkyl).

In compounds of structure II where G is the amido moiety (G1), that is



m is 0, 1, 2, 3 or 4; and R is H or alkyl.

In compounds of structure II where G is the amido moiety (G2), that is



p is 0, 1 or 2.

In compounds of structure II where G is (G3), that is



X¹ is NHCO, S, SO, SO₂ or O;

m is 0, 1, 2, 3, 4; and R is H or alkyl.


In compounds of structure II where G is (G4) that is



X¹ and p are as defined above.


In the above structures A is aryl or cycloalkyl, or an azacycloalkyl ring A1 of 3 to 7 carbons in the ring
 50 or an azacycloheteroalkyl ring A2 of 4 to 6 carbons in the ring,
 A1 or A2

55




- where X is CH₂ (to provide A1) or X is O or S (to provide A2);
 q is 0, 1, 2, 3 or 4 if X is CH₂;
 q is 2, 3 or 4 if X is O or S;
 Y¹ and Y² are independently H, lower alkyl, halo or keto; and
 provided that where X is a hetero atom (that is, A is azacycloheteroalkyl (A2)), then there must be at
 least a 2-carbon chain between X and any N atom in the ring A2 or outside ring A2.
 In addition, compounds of the invention I include compounds having the structure III

III



wherein R^{5'} is



where z is 0, 1 or 2;


- R¹⁰ is H, alkyl, cycloalkyl, aryl, cycloheteroalkyl or heteroaryl;
 R¹¹ is H, alkyl, CO₂R^c or CONR^aR^b;
 wherein R^c is H or alkyl; and
 R^a and R^b are independently selected from H, alkyl, cycloalkyl, cycloheteroalkyl, aryl, or heteroaryl;
 R^d is an amino acid side chain;
 t is 2, 3, 4 or 5;
 R is H, or lower alkyl; and
 R⁸ is (CH₂)_y-R¹², where y is 0, 1 or 2 and R¹² is cycloalkyl; heteroaryl; CO₂H; CONR^aR^b; or aryl
 optionally substituted with NO₂, OH, alkoxy, acyloxy,



halogen, alkyl, aryl, CO₂alkyl, CONHalkyl, alkylthio, arylthio, NHalkyl or NHcycloalkyl.

In addition, compounds of the invention I include compounds having the structure IV


IV



wherein s is 2, 3 or 4, and n, R⁵, R², R³, R and R¹ are as defined above, and R⁹ is H or CO₂R¹⁶ where R¹⁶ is H or alkyl.

All of the compounds of the invention I, II, III and IV include all stereoisomers thereof and pharmaceutically acceptable salts thereof.

Examples of the A1 or A2 rings (azacycloalkyl, or azacycloheteroalkyl) which may be employed herein include



and the like wherein the N- is connected to



45 The term "lower alkyl" or "alkyl" as employed herein by itself or as part of another group includes both straight and branched chain radicals of up to 18 carbons, preferably 1 to 8 carbons, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1, 2 or 3 halo substituents (for example, to form CF₃ or CF₃CH₂) and/or 1 or

50 2 of the following substituents: an aryl substituent (for example, to form benzyl or phenethyl), an alkyl-aryl substituent, a haloaryl substituent, a cyclo-alkyl substituent, an alkylcycloalkyl substituent, an alkenyl substituent, an alkynyl substituent, hydroxy or a carboxy substituent. It will be appreciated that the same "alkyl" group may be substituted with one or more of any of the above substituents.

The term "cycloalkyl" by itself or as part of another group includes saturated cyclic hydrocarbon groups containing 3 to 12 carbons, preferably 3 to 8 carbons, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, any of which groups may be substituted with substituents such as halogen, lower alkyl, alkoxy and/or hydroxy groups.

The term "aryl" or "Ar" as employed herein by itself or as part of another group refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, such as phenyl, or naphthyl. Aryl (or Ar), phenyl or naphthyl may include substituted aryl, substituted phenyl or substituted naphthyl, which may include 1 or 2 substituents on either the Ar, phenyl or naphthyl such as lower alkyl, cyano, amino, alkylamino, dialkylamino, nitro, carboxy, carboalkoxy, trifluoromethyl, halogen (Cl, Br, I or F), lower alkoxy, arylalkoxy, hydroxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, arylsulfinyl and/or arylsulfonyl.

The term "aralkyl", "aryl-alkyl" or "aryl-lower alkyl" as used herein by itself or as part of another group refers to lower alkyl groups as discussed above having an aryl substituent, such as benzyl.


The term "lower alkoxy", "alkoxy" or aralkoxy" includes any of the above lower alkyl, alkyl or aralkyl groups linked to an oxygen atom.

The term "halogen" or "halo" as used herein by itself or as part of another group refers to chlorine, bromine, fluorine or iodine with chlorine being preferred.

The term "lower alkenyl" or "alkenyl" as employed herein by itself or as part of another group includes a carbon chain of up to 16 carbons, preferably 3 to 10 carbons, containing one double bond which will be separated from "N" by at least one saturated carbon moiety such as $-(CH_2)_q-$ where q can be 1 to 14, such as 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 4-pentenyl and the like, and may include a halogen substituent such as I, Cl, or F.


The term "lower alkynyl" or "alkynyl" as employed herein by itself or as part of another group includes a carbon chain of up to 16 carbons, preferably 3 to 10 carbons, containing one triple bond which will be separated from "N" by at least one saturated carbon moiety such as $-(CH_2)_{q'}$ where q' can be 1 to 14, such as 2-propynyl, 2-butyryl, 3-butyryl and the like.

The term "heteroaryl" or heteroaromatic by itself or as part of another group refers to a 5- to 12-membered aromatic ring, preferably 5- or 6-membered aromatic ring, which includes 1 or 2 hetero atoms such as nitrogen, oxygen or sulfur, such as



and the like. The heteroaryl rings may optionally be fused to aryl rings defined previously. The heteroaryl rings may optionally include 1 or 2 substituents such as halogen (Cl, Br, F or CF_3), lower alkyl, lower alkoxy, carboxy, amino, lower alkylamino and/or dilower alkylamino.

The term "cycloheteroalkyl" as used herein refers to a 5-, 6- or 7-membered saturated ring which includes 1 or 2 hetero atoms such as nitrogen, oxygen and/or sulfur, such as



and the like.

The term "cycloheteroalkylalkyl" refers to a 5-, 6- or 7-membered saturated ring which includes 1 or 2 heteroatoms such as nitrogen, oxygen or sulfur, such as any of the cycloheteroalkyl rings as disclosed above, linked to a $(CH_2)_x$ chain wherein x is 1 to 12, preferably 1 to 8.

The term "amino acid side chain" refers to the side chain of any of the known alpha-amino acids such as the side chain of each of arginine, histidine, alanine, glycine, lysine, glutamine, leucine, valine, serine, homoserine, allothreonine, naphthylalanine, isoleucine, phenylalanine and the like.

Preferred are compounds of formula I wherein Z is (Z1) and G is (G2)



wherein p is 1 or 2, A is an azacycloalkyl ring



where q is 0 or 1; and

R¹ is OH, NH₂, CN or alkoxy;

R⁵ is lower alkylSO₂, arylalkylSO₂, H or HO₂C-alkyl-;

R⁴ is aralkyl or hydroxyalkyl;


R² and R³ are each H;

n is 0 or 1.

A more preferred embodiment of the heterocyclic thrombin inhibitors of the invention has the structure

IA


IA



where, R^4 is aralkyl (preferably benzyl), aryl (preferably phenyl), or arylalkoxyalkyl (preferably benzyloxymethyl) and R^5 is alkyl (preferably methyl, ethyl, trifluoro ethyl or propyl) or arylalkyl (preferably benzyl) and R^1 is OH or NH_2 , including all stereoisomers thereof.


Other preferred compounds of formula I are those wherein Z is (Z1), G is G1, n is 0 or 1; p is 2; R^5 is arylSO₂- or alkylSO₂- or HO₂C-alkyl-; R^4 is arylalkyl or hydroxyalkyl such as hydroxymethyl; R^2 is hydrogen or lower alkyl such as methyl or ethyl; R^3 is H; and compounds of formula IB:

IB




Other compounds preferred are compounds of formula I wherein Z is (Z1) and G is (G3) wherein X^1 is S or SO₂, n is 0, p is 1, m is 2

and R^1 is OH or NH_2 ; R^2 and R^3 are each H, R^4 is H or $-CH_2OH$, and R^5 is



or HO₂C-alkyl-.


Other preferred compounds are compounds of formula I wherein Z is (Z1) and G is (G4) R¹ is CN, NH₂, OH or OCH₃; R² and R³ are each H, p is 1, A is azacycloalkyl, R⁴ is hydroxymethyl or benzyl and R⁵ is



H, BOC or CBZ.

Preferred compounds of formula I wherein Z is (Z2) are compounds wherein t is 2, 3, 4 or 5, z is 0 or 1; R⁴ is optionally substituted phenyl, alkyl, hydroxyalkyl or aminocarbonylalkyl; R¹² is cycloalkyl, phenyl or H; y is 0, 1 or 2; R¹¹ is alkoxy carbonyl or alkyl; R¹⁰ is aryl or cycloalkyl; and R¹ is OH, NH₂, CN or OCH₃.

More preferred compounds of formula I wherein Z is (Z2) are compounds wherein p is 1; z is 1; y is 1; R¹² is p-NO₂C₆H₅, -o-FC₆H₅, or C₆H₅; R⁴ is




R¹⁰ is C₆H₅, or



R¹¹ is HOCH₂- or alkyl.

R¹ is CN, OH, NH₂, or OCH₃; R is H.


Preferred compound of formula I wherein Z is (Z3) are compounds wherein R⁵ is heteroarylsulfonyl, such as



R² and R³ are each H, R³ is CO₂alkyl, n is 1, p is 3, R is H and R¹ is CN, OH, NH₂, or OCH₃.

The compounds of formula I of the invention may be prepared according to the following reaction sequences.


The compounds of formula I of the invention wherein Z is (Z1) and G is (G1)
that is





may be prepared according to the following Reaction Sequence I.

Reaction Sequence I

A. $R^5 \neq H$




(R⁵ ≠ H and can be e.g. t-butoxycarbonyl (BOC), carbobenzyloxy (CBz))




40

$$\text{H}_2\text{N}-\text{CH}_2-(\text{CH}_2)_n-\text{CH}_2-\text{N}-\text{P}^1$$

(P¹=carbobenzyloxy, t-butoxycarbonyl, phthalimido)




50



Reduction to
remove P^1 -CBZ
1) H_2 , Pd/C or
TFA, when P^1 = α -BOC; or
hydrazine, when P^1 =
Phthalimido

2) BrCN, Base
3) NH_2R^1 (A)
or
 $NaN(CN)_2$ (B)


IA

B. $R^5 = H$ 

Deprotection

TFA if R^5 =BOC


IB




As seen in the above Reaction Sequence I, compounds of formula I are prepared as follows. The ester II is made to undergo a carbodiimide coupling reaction with protected amino acid III in the presence of ethyl 3-(3-dimethylamino)propyl carbodiimide hydrochloride (WSC) or dicyclohexylcarbodiimide (DCC), and 1-hydroxybenzo-triazole monohydrate (HOBT), and N-methylmorpholine (NMM), and in the presence of an inert organic solvent such as dimethylformamide (DMF), THF or N-methylpyrrolidone, to form the amide IV. Amide IV is hydrolyzed by treatment with alkali metal base such as NaOH or LiOH in the presence of an alcohol solvent such as methanol or ethanol. The reaction mixture is acidified with HCl, KHSO₄ or H₂SO₄, to form acid V. The acid V is then subjected to a carbodiimide coupling reaction wherein V is treated with protected amine VI in the presence of WSC or DCC, and HOBT, and NMM, in the presence of an inert organic solvent such as dimethylformamide, THF or N-methylpyrrolidone, to form amide VII. The amide VII is then dissolved in an alcohol solvent such as ethanol or methanol, to which HCl has been added and the mixture is hydrogenated over Pd-C or Pd(OH)₂-C in the case where P¹ is carbobenzyloxy. The crude material is separated by conventional procedures and the desired isomers are treated with cyanogen bromide and base, followed by amine A or cyanide B in the presence of an alcohol solvent such as methanol or ethanol to form the compound of the invention IA where R⁵ ≠ H.

Compounds of the invention where R⁵ is H may be formed by deprotecting IA by treatment with trifluoroacetic acid (TFA) when R⁵ is t-butoxycarbonyl (BOC) or H₂-Pd/C when R⁵ is carbobenzyloxy (CBz), with or without the presence of dry inert organic solvent such as dichloromethane, chloroform or THF, at temperatures within the range of from about -15° to about 20° C, to form IB.

The compounds of formula I of the invention where Z is (Z1) and G is (G2)




wherein A is azacycloalkyl or azacycloheteroalkyl, may be prepared according to the following Reaction Sequence II:





Reaction Sequence IIA. where $R^5 \neq H$ 

(where P^1 is a protecting group such as BOC or CBz)


Coupling Reaction

WSC or DCC
HOBT
NMM






B. where $R^5 = H$



As seen in the above Reaction Sequence II, compounds of formula I wherein Z is (Z1) and G is (G2), that is




30 and A is azacycloalkyl or azaheteroalkyl, are prepared as follows. The protected acid V is made to undergo a carbodiimide coupling reaction with amine VIII in the presence of ethyl 3-(3-dimethylamino)propyl carbodiimide hydrochloride (WSC) or dicyclohexylcarbodiimide (DCC), and 1-hydroxybenzotriazole monohydrate (HOBT), and N-methylmorpholine (NMM), and in the presence of an inert organic solvent such as dimethylformamide (DMF), THF or N-methylpyrrolidone to form the amide IX. Amide IX is deprotected by

35 treatment with, for example, $H_2/Pd-C$ if P^1 is CBz, and is then treated with cyanogen bromide to form Compound X. Compound X is treated with amine A or cyanide B in the presence of alcohol solvent, such as ethanol to form amine IC of the invention where $R^5 \neq H$.

Compounds of the invention ID where R^5 is H are prepared by deprotection of IC by treatment with trifluoroacetic acid (if $P = BOC$), with or without the presence of dry inert organic solvent such as dichloromethane, chloroform or THF, at temperatures within the range of from about -15° to about $20^\circ C$.

The starting materials of formula VIII are known in the art or may be prepared by those skilled in the art employing conventional techniques.


The compounds of formulae I and IA of the invention where Z is (Z1) and G is (G2) that is



20 where A is aryl or cycloalkyl may be prepared according to the following Reaction Sequence III:

Reaction Sequence III

25 A. $R^5 \neq H$



Coupling
Reaction


IE

WSC or DCC
HOBT
NMM


VIIIA

(A^1 is aryl or
cycloalkyl)

35 B. $R^5 = H$



As seen in Reaction Sequence III, compounds of formulae I and I'' where G is




are prepared as follows. The protected acid V is subjected to a carbodiimide coupling reaction wherein V is treated with protected amine VIIIA in the presence of WSC or DCC, and HOBT, and NMM, in the presence of an inert organic solvent such as dimethylformamide, THF or N-methylpyrrolidone, to form amide of the invention IE where $R^5 \neq H$. The amide IE may be dissolved in an alcohol solvent such as ethanol or methanol, to which HCl has been added and the mixture is hydrogenated over Pd-C or Pd(OH)₂-C, in the case where R^5 is carbobenzyloxy, to form compounds of the invention IF where R^5 is H.

The starting compound VIIIa is known in the art or may be prepared employing conventional procedures.


The starting acid V may be prepared from ester IV by hydrolyzing ester IV by treating with a base such as NaOH, KOH or LiOH and then neutralizing the resulting alkali metal salt with strong acid such as HCl or oxalic acid.

The compounds of formula I of the invention where Z is (Z1) and G is (G3) $-\text{CH}_2-\text{X}'-(\text{CH}_2)_m-\text{CH}_2\text{NR}$ wherein X' is S, SO, or SO₂, that is



may be prepared according to the Reaction Sequence IV

Reaction Sequence IV

A. where $R^5 \neq H$:




35




55

Referring to Reaction Sequence IV compounds of formula I wherein Z is (Z1), G is (G3) and X' is S, SO or SO₂ may be prepared starting with tosylate X (J. Med. Chem. 35, 2610 (1992)) (wherein PG in X is a protecting group such as




15 (fluorenylmethoxycarbonyl, Fmoc); preferably BOC, which is subjected to a displacement reaction wherein X is treated with potassium thioacetate (KSAc) in the presence of an inert organic solvent such as acetone, dimethylformamide (DMF) or tetrahydrofuran (THF), under an inert atmosphere such as argon, at a temperature within the range of from about 0° to about 100°C to form thioacetate XII. Thioacetate XII is then alkylated by reacting XII with an alkali metal alkoxide such as sodium methoxide or potassium t-butoxide in an inert organic solvent such as THF, DMF or diethylether, in the presence of an alcohol solvent such as methanol or ethanol under an inert atmosphere such as argon, at a temperature within the range of from about -30° to about 50°C. To the resulting solution is added N-bromoalkyl-phthalimide C to form the thiophthalimide XIII. Thiophthalimide XII is deprotected by treatment with a deprotecting agent such as trifluoroacetic acid where PG is BOC or HBr/acetic acid where PG is CBZ, with or without the presence of

25 dry inert organic solvent such as dichloromethane, chloroform or THF, to form a crude amine salt XIII A.



40 The resulting salt XIII A is made to undergo a carbodiimide coupling reaction with protected amino acid D



50 (wherein R⁵ serves as a protecting group) in the presence of 1-hydroxybenzotriazole monohydrate (HOBT), ethyl-3-(3-dimethylamino)propyl carbodiimide (WSC) or dicyclo-hexylcarbodiimide (DCC) and N-methylmorpholine (NMM), in the presence of an inert organic solvent such as dimethylformamide (DMF), THF or N-methyl-pyrrolidone, to form XIV.

55 XIV is then reacted with anhydrous hydrazine in the presence of dry solvent such as dichloromethane, chloroform or THF, and an alcohol solvent such as methanol or ethanol, to form thioalkylamine compound XV. Compound XV is then reacted with cyanogen bromide and then with amine A or cyanide B, as described hereinbefore, to form compound of the invention IG.


Compound IG may be oxidized to the corresponding sulfoxide IJ or to the corresponding sulfone IK.




The oxidation is carried out with an oxidizing agent such as m-chloroperbenzoic acid (MCPBA), oxone or sodium periodate in the presence of an inert organic solvent such as dichloromethane, employing from about 0.9 to about 1.5 moles of oxidizing agent per mole of amide, to form the corresponding sulfoxide. The corresponding sulfone may be formed employing from about 2 to about 3 moles of oxidizing agent per mole of amide.

Compounds of formula IG of the invention where R⁵ is H are prepared by deprotecting IG as described hereinbefore, to form IH where R⁵ is H.

The compounds of the Formula I of the invention where Z is (Z1) and G is (G4) -CH₂-X¹-(CH₂)_p-A- wherein X¹ is S, SO, or SO₂ and A is azacycloalkyl or azacycloheteroalkyl may be prepared according to Reaction Sequence V.

Reaction Sequence V









30



The compounds of the Formula I of the invention where Z is (Z1) and G is (G4) -CH₂-X¹-(CH₂)_p-A- wherein X¹ is S, SO, or SO₂ and A is aryl or cycloalkyl may be prepared according to Reaction Sequence VI.

35

Reaction Sequence VI








The compounds of Formula I of the invention where Z is (Z1) and G is (G4) -CH₂-X¹-(CH₂)_p-A-wherein X¹ is O may be prepared according to Reaction Sequence VII.

10






Referring to Reaction Sequence V, compounds of formula I of the invention wherein Z is (Z1), G is (G4) and A is azacycloalkyl or azacycloheteroalkyl may be prepared by treating XII with an alkali metal alkoxide followed by a compound of formula $Br(CH_2)_p-A-PG'$ where PG' is a protecting group different from PG, to give XVI. Compounds ILa, IMa, INa and IOa are prepared using the steps described in Reaction Sequence IV.

Referring to Reaction Sequence VI, compounds of formula I of the invention where Z is (Z1), G is (G4) and A is aryl or cycloalkyl may be prepared by reacting XII with an alkali metal alkoxide followed by a compound of formula $Br-(CH_2)_p-A-CN$ to give XVIII. Compounds ILb, IMb, INb, and IOb are prepared using the steps described previously.





The key step for the preparation of compounds wherein X' is oxygen is shown in Scheme VII. Treatment of the protected alcohol XX with KOH and a mesylate (Ms) of formula XXI in xylene (J. Med. Chem 1986, 29, 2335-2347) will provide the series of compounds XXII. Further steps in the preparation of compounds of formula I wherein X' is oxygen may be effected in analogy with the previously described Schemes to form compounds IP, IQ, IR and IS of the invention.


The compounds of formula I of the invention where Z is (Z1) and G is (G3) or (G4) and X' is NHCO that is



may be prepared according to the following Reaction Sequence VIII.

Reaction Sequence VIII






As seen in Reaction Sequence VIII, compounds of Formula I of the invention wherein Z is (Z1) and G is (G3) or (G4) and X^1 is $-NHCO-$ are prepared as follows. Tosylate XI is made to undergo a displacement reaction with sodium azide in the presence of an inert organic solvent such as dimethylsulfoxide (DMSO) or dimethylformamide (DMF), at a temperature within the range of from about 50° to about 90° C, to form azide XXXIII which is reduced by reaction with a reducing agent such as $H_2/Pd-C$ or triphenylphosphine/ H_2O , lithium aluminum hydride (LAH) or stannous chloride, to form the corresponding amine XXIV.


The amine XXIV is made to undergo a coupling reaction with a compound $W'COOH$ of formula XXV to give a compound of formula XXVI (G is (G3)), or XXVII (G is (G4) and A is azacycloalkyl or azacycloheteroalkyl), or XXVIII (G is (G4) and A is aryl or cycloalkyl). The compound of formula XXVI may be converted into a compound of the invention of formula IT by previously described methods. Compounds of formula XXVII or XXVIII may be converted into a compound of formula IU by previously described methods. Both IV and IW ($R^5 = H$) may be prepared from compounds of formula IT or IU by removal of R^5 .


where R⁵ is a protecting group.

The compounds of formula I of the invention where Z is (Z2) that is



may be prepared according to the following Reaction Sequence IX.

Reaction Sequence IX



PG, PG¹, and PG² may be the same or different and are protecting groups such as t-butoxycarbonyl or benzyloxycarbonyl.


Referring to the above Reaction Sequence IX, compounds of formula I of the invention where Z is (Z2) may be prepared starting with amine XXIX which is made to undergo a carbodiimide coupling reaction with protected amino acid XXX in the presence of ethyl 3-(3-dimethylamino)propylcarbodiimide hydrochloride (WSC) or dicyclohexylcarbodiimide (DCC), 1-hydroxy-benzotriazole (HOBT) monohydrate, N-methylmorphine (NMM), and an inert organic solvent such as dimethylformamide (DMF) or dichloromethane under an inert atmosphere, such as argon, to form amide XXXI.

Amide XXXI is subjected to a deprotection reaction wherein amide XXXI (if P = butoxycarbonyl) is treated with trifluoroacetic acid (TFA) in the presence of dry inert organic solvent such as dichloromethane, under an inert atmosphere such as argon, at reduced temperature of from about 0° to about 20°C, to form the TFA salt. The TFA salt is added to a mixture of protected amino acid XXXII, HOBT, WSC or DCC, in solvent under an inert atmosphere such as argon at a reduced temperature of from about 0 to about 20°C. NMM is added and the reaction is allowed to go to completion to form dipeptide XXXIII.

Dipeptide XXXIII is then deprotected with TFA to form the TFA salt which is coupled with protected amino acid XXXIV employing WSC or DCC, HOBT and NMM to form protected tripeptide XXXV.


The protected tripeptide XXXV is deprotected to tripeptide XXXVI which is subjected to a modified guanidine forming reaction by, for example, reaction with cyanogen bromide in the presence of sodium acetate and an alcohol solvent such as methanol, and then reaction with amine A or cyanide B in the presence of acid, such as HCl, alcohol such as methanol and weak base such as sodium carbonate, to form compound of the invention IY.

The compounds of formula I of the invention where Z is (Z3), that is



may be prepared according to the following Reaction Sequence X.

Reaction Sequence X



As seen in Reaction Sequence IX, compounds of the invention I wherein Z is (Z3), that is I^{VI} may be prepared by coupling acid XXXVII with compound XXXVIII in the presence of ethyl-3-(3-dimethylamino)-propyl carbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, N-methyl morpholine and an inert organic solvent such as dimethylformamide (DMF) to form amide XXXIX. Amide XXXIX is deprotected by treating XXXIX with H_2/Pd to form amide XL which is treated with cyanogen bromide in the presence of sodium acetate to form cyanide XLI. The cyanide XLI is then treated with amine A or cyanide B in the presence of base such as triethylamine, and alcohol solvent such as methanol to form compound IZ of the invention.

The compounds of formula I of the invention can be obtained as pharmaceutically acceptable acid addition salts by reacting a free base with an acid, such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, citric, maleic, succinic, lactic, tartaric, gluconic, benzoic, methanesulfonic,

ethanesulfonic, benzenesulfonic, p-toluenesulfonic acid or the like.

The compounds of the present invention are serine protease inhibitors, and in particular may inhibit thrombin, Factor Xa, and/or trypsin. The compounds of the present invention are useful for the treatment or prophylaxis of those processes which involve the production and/or action of thrombin. This includes a number of thrombotic and prothrombotic states in which the coagulation cascade is activated which include, but are not limited to, deep vein thrombosis (DVT), disseminated intravascular coagulopathy (DIC), Kasabach-Merritt syndrome, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery (such as hip replacement and endarterectomy) and peripheral arterial occlusion. In addition to its effects on the coagulation process, thrombin has been shown to activate a large number of cells (such as neutrophils, fibroblasts, endothelial cells, smooth muscle cells). Therefore, the compounds of the present invention may also be useful for the treatment or prophylaxis of adult respiratory distress syndrome, septic shock, septicemia, inflammatory responses which include, but are not limited to, edema, acute or chronic atherosclerosis, and reperfusion damage.

The compounds of the invention may also be useful in treating neoplasia/metastasis (in particular those which utilize fibrin) and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In addition, the compounds of the present invention may be useful to prevent restenosis following arterial injury induced by endogenous (rupture of an atherosclerotic plaque) or exogenous (invasive cardiologic procedure) events.

The compounds of the present invention may also be used as an anticoagulant in extracorporeal blood circuits, such as those necessary in dialysis and surgery (such as coronary artery bypass surgery).

The compounds of the present invention may also be used in combination with thrombolytic agents, such as tissue plasminogen activator (natural or recombinant), streptokinase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators, and the like. The compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. The compounds of the present invention may also allow for reduced doses of the thrombolytic agent to be used and therefore minimize potential hemorrhagic side-effects.

The compounds of the present invention may also be used in combination with other antithrombotic or anticoagulant drugs such as thromboxane receptor antagonists, prostacyclin mimetics, phosphodiesterase inhibitors, fibrinogen antagonists, and the like.

Compounds of the present invention that inhibit trypsin may also be useful for the treatment of pancreatitis.


The compounds of the invention can be administered orally or parenterally to various mammalian species known to be subject to such maladies, e.g., humans, cats, dogs and the like in an effective amount within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) on a regimen in single or 2 to 4 divided daily doses.

The active substance can be utilized in a composition such as tablet, capsule, solution or suspension containing about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formula I. They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc., as called for by accepted pharmaceutical practice.

The following Examples represent preferred embodiments of the present invention. Unless otherwise indicated, all temperatures are expressed in degrees Centigrade.

Example 1

N-[[1-[(Hydroxyamino)iminomethyl]-4-piperidinyl]-methyl]-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalanyl]-L-prolinamide, trifluoroacetate (1:1) salt



A. N-[(1,1-Dimethylethoxy)carbonyl]-4-methylamino piperidine

Benzaldehyde (14.6 g, 0.138 mmol), 4-(aminomethyl)-piperidine (14.29 g, 0.125 mmol) and toluene (250 mL) were combined and heated at reflux for 4.5 h with removal of water. The reaction mixture was cooled to -25 °C and di-*t*-butyl dicarbonate (28.7 g, 0.131) was added. The reaction mixture was allowed to warm to room temperature and stirred an additional 8 h. To this reaction mixture was added aqueous KHSO₄ (1.0 M, 120 mL) and stirred for 3 h. The organic layer was removed and the remaining aqueous layer was extracted with ether (3x75 mL). The aqueous layer was made basic through the addition of aqueous NaOH (1.0 M, 130 mL) and extracted with ether (3x75 mL). The combined organic extracts were dried over NaSO₄ filtered, and the solvent removed in vacuo to give title compound, 24.4 g (91 %), as a white solid.

B. N-[(Phenylmethoxy)-carbonyl]-D-phenylalanyl-L-proline methyl ester

To a solution of N-CBZ-D-phenylalanine (47.3 g, 0.158 mmol) in DMF (300 mL) at 0 °C, was added L-proline-methylester.HCl (25.0 g, 0.151 mmol), 1-hydroxybenzotriazole hydrate (20.28 g, 0.166 mmol), ethyl-3-(3-dimethylamino)-propyl carbodiimide.HCl (31.8 g, 0.166 mmol) and 4-methylmorpholine (16.0 g, 0.159 mmol). The reaction mixture was stirred for 8 h while allowing the reaction to warm to room temperature. The reaction mixture was poured in water (1.2 L) and extracted with ethyl acetate (3x300 mL). The combined organic extracts were washed as follows: KHSO₄ (0.25 M, 2x200 mL), water (1x200 mL), saturated aqueous NaHCO₃ (2x200 mL) and saturated NaCl (1x200 mL). The organic layer was dried over MgSO₄, filtered and the solvent removed in vacuo to give title compound, 60.9 g (98 %), as an oil.

C. N-[(Phenylmethoxy)-carbonyl]-D-phenylalanyl-L-proline

To a solution of Part B compound (57.8 g, 0.141 mol) in MeOH (180 mL) and THF (60 mL) at 0 °C was added aqueous NaOH (1.0 N, 183 mL). After 30 min the reaction mixture was warmed to room temperature and stirring continued for an additional 4 h. Aqueous HCl (1.0 N, 42 mL) was added and the organic solvents removed in vacuo. The resulting aqueous layer was acidified to pH of 2-3 and extracted with ethyl acetate (2x300 mL). The combined extracts were dried over MgSO₄, filtered and the solvent removed in vacuo to give title compound, 45.53 g (97 %), as a white solid.

D. N-[[1-[(1,1-Dimethylethoxy)carbonyl]-4-piperidinyl]methyl]-1-[N-[(phenylmethoxy)carbonyl]-D-phenylalanyl]-L-prolinamide

To a solution of Part C compound (19.39 g, 48.90 mmol) in DMF (120 mL) at 0 °C, was added Part A compound (9.98 g, 46.57 mmol), 1-hydroxybenzotriazole hydrate (6.26 g, 51.23 mmol) and ethyl-3-(3-

dimethylamino)propyl carbodiimide HCl (9.82 g, 51.23 mmol). The reaction mixture was stirred for 12 h while allowing the reaction to warm to room temperature. The reaction mixture was poured in water (500 mL) and extracted with ethyl acetate (3x100 mL). The combined organic extracts were washed as follows: KHSO₄ (0.25 M, 2x50 mL), water (1x75 mL), saturated aqueous NaHCO₃ (2x75 mL) and saturated NaCl (1x50 mL). The organic layer was dried over MgSO₄, filtered and the solvent removed in vacuo to give title compound, 23.4 g (85 %), as an oil.

E. N-[[1-[(1,1-Dimethylethoxy)carbonyl]-4-piperidinyl]methyl]-1-[D-phenylalanyl]-L-prolinamide

To a stirred solution of Part D compound (15.00 g, 25.3 mmol) in MeOH (150 mL) was added Pd/C (1.50 g) and the reaction mixture was placed under 1 atmosphere of hydrogen. An additional Pd/C (2.5 g) was added after stirring for 2 h. The reaction was complete after stirring 8 more hours. The reaction mixture was filtered and the solvent removed in vacuo to give title compound, 11.41 g (91 %), as a white solid.

F. N-[[1-[(1,1-Dimethylethoxy)carbonyl]-4-piperidinyl]methyl]-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalanyl]-L-prolinamide

To a solution of Part E compound (1.21 g, 2.5 mmol) and triethylamine (1.1 mL, 7.9 mmol) in chloroform (5.7 mL) at 0 °C under argon was added benzylsulfonyl chloride (0.482 g, 2.5 mmol). After 3.25 hr, triethylamine (0.5 mL, 3.6 mmol) and benzylsulfonyl chloride (0.39 g, 2.0 mmol) were added. After 2.75 h, the mixture was diluted with 0.25 M aqueous KHSO₄ and EtOAc. After separation of the two layers, the organic layer was washed with 0.25 M aqueous KHSO₄, H₂O, saturated aqueous NaHCO₃, and H₂O, successively; dried over NaSO₄, filtered and concentrated in vacuo to give title compound, 1.37 g (90 %).

G. N-[[1-[(1-Dimethylethoxy)carboxyl]-4-(N-cyano)piperidinyl]methyl]-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalanyl]-L-prolinamide

To a solution of Part F compound (1.4 g, 2.2 mmol) in dichloromethane (9.0 mL) under nitrogen at 0 °C was added 4 N HCl-dioxane (14 mL, 25 mmol). After 5 min., the 0 °C bath was removed. The reaction was stirred for 1.5 h and concentrated in vacuo to give crude N-(4-piperidinyl)methyl-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalanyl]-L-prolinamide, hydrochloride salt. To a solution of crude HCl salt (2.24 mmol), triethylamine (1.3 mL, 9.3 mmol) and sodium acetate (0.74 g, 9.6 mmol) in methanol (10 mL) was added cyanogen bromide (0.71 g, 6.7 mmol). After 21.5 h, the reaction mixture was concentrated in vacuo. The material was dissolved in EtOAc and H₂O. After separation, the organic layer was dried over MgSO₄, filtered and concentrated in vacuo to give crude title compound.

H. N-[[1-[(Hydroxyamino)iminomethyl]-4-piperidinyl]methyl]-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalanyl]-L-prolinamide, trifluoroacetate (1:1) salt


To crude Part G compound was added a solution of hydroxylamine in methanol [prepared by stirring hydroxylamine • HCl (1.9 g, 27.0 mmol) and Na₂CO₃ (1.4 g, 13.5 mmol) in methanol (36 mL) for 15 min. and filtering the precipitate]. After 7.5 h, the precipitate was filtered, and the filtrate was concentrated in vacuo and purified by preparative HPLC to give title compound, 0.20 g (11 %) as a white solid:
[α]_D = -44.5° (c = 0.56, MeOH)

Anal. Calc'd for C₂₈H₃₈N₆O₅S • 1.2 TFA • 1.05 H₂O:

	C, 50.26;	H, 5.73;	N, 11.57;	S, 4.41;	F, 9.41
Found:	C, 50.26;	H, 5.81;	N, 11.50;	S, 4.10;	F, 9.42

Example 2

N-[[1-[(Cyanoamino)iminomethyl]-4-piperidinyl]-
 methyl]-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalan-
 yl]-L-prolinamide



To a stirred mixture of Example 1 Part G compound (500 mg, 0.89 mmol) in 10 mL of n-BuOH under argon was added sodium dicyanamide (197 mg, 2.22 mmol). This mixture was heated to reflux under argon for 18 h and cooled to room temperature. The mixture was concentrated in vacuo and diluted with 240 mL of EtOAc. The solution was washed with 0.25 M KHSO₄ solution (2x60 mL), saturated NaHCO₃ solution (1x60 mL) and brine (1x60 mL), the organic layer dried (MgSO₄), filtered and concentrated in vacuo, and chromatographed on silica gel to give 260 mg (50%) of title compound.
 $[\alpha]_D = -62.1^\circ$ (c=0.94, CHCl₃)


Anal. Calc'd for C₂₉H₃₇N₇O₄S•0.26H₂O:

	C, 59.59;	H, 6.47;	N, 16.78;	S, 5.49
Found:	C, 59.34;	H, 6.52;	N, 17.03;	S, 5.33


mp 125-130° C

Example 3

N-[[1-[(Hydroxyamino)iminomethyl]-4-piperidinyl]-4-piperidinyl]-
methyl]-1-[N-[methylsulfonyl]-D-phenylalanyl]-L-
prolinamide




A.




Following the procedure published in Synthetic Communication, 22(16), p 2357-2360, 1992, the title compound was obtained.

B.




To a stirred solution of methylsulfonylamido-D-phenylalanylproline (3.18 g, 9.35 mmol), Part A amine (2.00 g, 9.35 mmol) and 1-hydroxybenzotriazole monohydrate (1.58 g, 9.35 mmol) in 60 mL of DMF was added in order N-methylmorpholine (3.29 mL, 29.9 mmol) and ethyl-3-(3-dimethylamino)propyl carbodiimide hydrochloride (1.79 g, 9.35 mmol). The reaction solution was stirred at room temperature for 20 h and concentrated under pump vacuum at 45 °C. The oily residue was dissolved in 300 mL of EtOAc and washed with 1N HCl solution (2x150 mL), saturated NaHCO₃ solution (2x150 mL) and brine (1x150 mL). The organic layer was dried (MgSO₄), filtered, concentrated in vacuo and chromatographed on Merck silica gel to give 4.21 g (84%) of title carbamate.

C. N-[(4-Piperidinyl)methyl]-1-[N-[(methyl)-sulfonyl]-D-phenylalanyl]-L-prolinamide,
hydrochloride salt




To a stirred solution of Part B carbamate (1.25 g, 2.33 mmol) in 10 mL of dichloro-methane was added 0°C 4N HCl in dioxane (15.0 mL, 60.0 mmol). The reaction solution was stirred at room temperature for 1 h and concentrated in vacuo. The oily residue was dissolved in 40 mL of methanol and then concentrated in vacuo to give 1.10 g (quantitative) of title amine hydrochloride.

D.



To a stirred solution of Example 3 Part C amine·HCl (1.36 g, 2.88 mmol) and anhydrous NaOAc (1.18 g, 14.4 mmol) in 10 mL of methanol was added cyanogen bromide (0.61 g, 5.76 mmol). This heterogeneous mixture was stirred at room temperature for 3.5 h and concentrated in vacuo. Purification was effected by flash chromatography on silica gel to give 1.30 g (98%) of title aminonitrile. 6% CH₃OH/CH₂Cl₂, R_f = 0.55, I₂.

E. N-[[1-[(Hydroxyamino)iminomethyl]-4-piperidinyl]-methyl]-1-[N-(methylsulfonyl)-D-phenylalanyl]-L-prolineamide




To a stirred solution of hydroxyamine hydrochloride (2.01 g, 28.9 mmol) in 38 mL of methanol was added solid sodium carbonate (1.52 g, 14.3 mmol). This suspension was stirred at room temperature for 15 min and the insoluble material filtered off. The filtrate was then combined with Part D compound, the reaction stirred at room temperature for 3 h, concentrated in vacuo and purified by preparative HPLC to give 580 mg (33%) of the title compound.

$[\alpha]_D = -57.5^\circ$ (c = 0.52, MeOH)

Anal. Calc'd for $C_{22}H_{34}N_6O_5S \cdot 2.30C_2F_3O_2H$:					
	C, 42.21;	H, 4.83;	N, 11.10;	S, 4.24;	F, 17.32
Found:	C, 42.21;	H, 4.98;	N, 10.91;	S, 4.36;	F, 17.13

Example 4

N-[[1-[(Cyanoamino)iminomethyl]-4-piperidinyl]-methyl]-1-[N-(methylsulfonyl)-D-phenylalanyl]-L-prolinamide




To a stirred solution of Example 3 Part D compound (220 mg, 0.40 mmol) in 3.0 mL of n-BuOH was added sodium dicyanamide (99.0 mg, 1.00 mmol). The reaction mixture was heated to reflux for 14 h and concentrated in vacuo. This was purified by preparative HPLC to give 124 mg (57%) of title compound.

Anal. Calc'd for $C_{23}H_{33}N_7O_4S \cdot 0.80H_2O \cdot 0.25C_2F_3O_2H$:					
	C, 51.65;	H, 6.43;	N, 17.94;	S, 5.87;	F, 2.61
Found:	C, 51.68;	H, 6.45;	N, 18.29;	S, 5.58;	F, 2.81

Example 5

N-[[1-[(Methoxyamino)iminomethyl]-4-piperidinyl]-methyl]-1-[N-[(methyl)sulfonyl]-D-phenylalanyl]-L-prolinamide




To a stirred solution of Example 3 Part D aminonitrile (0.34 g, 0.74 mmol) in 3.0 mL of 1-methyl-2-pyrrolidinone was added methoxyamine·HCl (0.18 g, 216 mmol). This reaction solution was immersed into a 85 °C oil bath. The bath temperature was slowly raised up to 130 °C in 80 min. The reaction solution was stirred at 130 °C for 2 h and cooled to room temperature. The solution was diluted with 30 mL of ether and the solution was decanted. The remaining oily residue was purified by preparative HPLC to give 250 mg (51%) of title compound.


Anal. Calc'd for $C_{23}H_{36}N_6O_5S \cdot 0.80H_2O \cdot 1.25C_2F_3O_2H$:					
	C, 46.02;	H, 5.88;	N, 12.63;	S, 4.82;	F, 10.70
Found:	C, 46.09;	H, 5.73;	N, 12.49;	S, 4.95;	F, 10.69

Example 6


[1S[2R*(3R*)]]-N-[2-[2[[[1-((Hydroxyamino)imino-
methyl))-3-piperidiny]carbonyl]amino]methyl]-1-
pyrrolidiny]l-1-(hydroxymethyl)-2-oxoethyl]-2-
naphthalene sulfonamide, trifluoroacetate salt



A.




A(1).



2-Azido-N-BOC pyrrolidine (2.13g, 9.4 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (7 mL) and stirred at RT 3 hours. The TFA and dichloromethane were removed by distillation under reduced pressure and by coevaporation with toluene to give the amine as a TFA salt. This and N-BOC-O-benzyl-L-serine (2.95g, 10 mmol) were dissolved in DMF (50 mL). HOBT (1.35g, 10 mmol), WSC (1.91g, 10 mmol) and NMM (3.3 mL, 30 mmol) were added. The reaction was stirred for 8 h at room temperature, diluted with ethyl acetate (50 mL) and saturated KHSO_4 solution (30 mL). The layers were separated and the aqueous layer was reextracted with saturated sodium bicarbonate solution (30 mL) and 10% lithium chloride solution (30 mL). The ethyl acetate layer was dried over magnesium sulfate and


concentrated in vacuo to provide title A(1) compound (3.87g, 100%) as an oil which was used without further purification.

A (2) .




Part A(1) BOC-azide (3.85 mg, 9.55 mmol) was dissolved in TFA (20 mL) and stirred at RT 1.5 hours. The TFA was removed by distillation under reduced pressure and by coevaporation with toluene. The residue was dissolved in dichloromethane (100 mL), cooled in an ice bath, and triethylamine (4.0 mL, 28.7 mmol) and 2-naphthyl sulfonyl chloride (2.00 g, 10.5 mmol) were added. The cooling bath was removed and the solution was stirred for 2 h. This solution was washed with KHSO₄ solution (25mL x 2) and NaHCO₃ solution(25 mL x 2), dried over magnesium sulfate and evaporated to provide crude A(2) which was chromatographed on silica gel to provide A(2) sulfonamide (2.60 g, 55%).

A (3) .




The Part A(2) azide (2.5g, 5 mmol) was dissolved in absolute ethanol (100 mL) and treated with 10% palladium on carbon (300 mg) and hydrogen gas at room temperature overnight. The catalyst was then removed by filtration through Celite, the pad washed with ethanol, and the solvent removed in vacuo to give title A amine as a foam (2.24 g, 96%).

B.

B(1). Ethyl nipecotate, D-tartrate salt


Ref: Johnston, G.A.R. et al, J Neurochemistry, 1976, Vol 26, pp.1029-1032. Ethyl nipecotate (50g, 318 mmol) and D-tartaric acid (47.74 g, 318 mmol) were dissolved in hot abs. ethanol (250 mL). A very small amount of insoluble material was removed by filtration through a pad of Celite. The filtrate gave crystalline material on cooling. This was harvested and recrystallized eight times from absolute ethanol to give title compound as a white solid (27 g). m.p. 155-156°C., $[\alpha]_{365} = -200.7^\circ$ (c = 2.0, 0.2% aqueous ammonium molybdate).

B(2).




The Part B(1) tartrate salt (1.0 g) was dissolved in water (5 mL) and a solution of potassium carbonate was added to bring the pH to 9. The solution was cooled in an ice water bath and ether (5 mL) was added. Benzyl chloroformate (0.5 mL) was added dropwise to the well-stirred solution. During the addition, the pH was maintained between 8 and 9 by addition of potassium carbonate solution. After addition was complete, the mixture was stirred cold for an additional 1.5 hours, maintaining the pH throughout this period. The layers were separated and the aqueous was reextracted with ether. The combined ether layers were dried over magnesium sulfate and concentrated in vacuo. The ethyl ester obtained was purified on silica gel, the purified material (930 mg) was dissolved in methanol (8 mL) and treated with 1 N NaOH solution (4 mL). After stirring at room temperature two hours, the methanol was removed in vacuo. The aqueous solution was acidified with 1 N HCl and the acid was extracted into ethyl acetate (2 x 10 mL), the combined extracts dried over magnesium sulfate and concentrated in vacuo to give title compound as a crystalline solid. (773 mg). $[\alpha]_D = +49.9^\circ$ (c = 1.4, MeOH). The optical purity of this material was determined by coupling some of this material with (S)-(-)-a-methyl-benzylamine. The material obtained was submitted to analytical HPLC for determination of purity and was found to be 97.6%, (e.e. = 95.2%).

B (3) .




Part A amine (820 mg, 1.75 mmol) and Part B(2) acid (526mg, 2.0 mmol) were dissolved in DMF (20 mL) at RT. HOBT (270 mg, 2 mmol), N-methyl morpholine (1.5 mL) and WSC (400mg, 2 mmol) were added. The reaction was stirred 24 hours at room temperature. The mixture was then diluted with ethyl acetate (75mL) and KHSO₄ solution (30 mL) and the layers were separated. The organic layer was washed with saturated NaHCO₃ solution (20 mL) and 10% lithium chloride solution (2 x 20 mL), dried over magnesium sulfate and concentrated *in vacuo*. The crude oil was chromatographed on silica gel, eluting with 50% EtOAc in hexane followed by 70% EtOAc in hexane and finally with EtOAc to provide title compound as a foam (830 mg, 67%).

B (4) .




Part B(3) compound (820 mg, 1.15 mmol) was dissolved in ethanol (100 mL) to which acetyl chloride (2.5 mL) had been added and the mixture was treated with 10% palladium on carbon (250 mg) and hydrogenated at 55 psi for 44 h. The catalyst was removed by filtration and the pad was washed with EtOH. The filtrate was concentrated *in vacuo* to obtain crude title B compound.

C.



The crude Part B hydrochloride salt (509 mg, 0.97 mmol) was dissolved in methanol (4 mL) and sodium acetate (463 mg) was added. While stirring, a solution of cyanogen bromide (117 mg, 1.1 mmol) in methanol (15 mL) was added dropwise over a period of three hours. Additional sodium acetate (600 mg) was added and stirring was continued for four hours. The solvent was removed *in vacuo* and the residue was partitioned between water and dichloromethane. The layers were separated and the dichloromethane solution was dried over magnesium sulfate, filtered and freed of solvent *in vacuo* to give title compound (464 mg) which was used without purification.

D.




Hydroxylamine hydrochloride (647 mg, 9.3 mmol) in methanol (10 mL) was treated with sodium carbonate (492 mg, 4.65 mmol). The mixture was stirred 15 minutes and filtered. The filtrate was added to the crude Part A cyano compound (0.93 mmol) and stirred at room temperature for three hours. The solvent was removed *in vacuo*. The crude material was purified by preparative HPLC to provide title compound as a white solid (315 mg, 49%).
 $[\alpha]_D = -15.5^\circ$ (c=0.5, MeOH)

Analysis calcd for 1.2 TFA + 0.7 H₂O:


	C, 47.28;	H, 5.30;	N, 12.07;	F, 9.83;	S, 4.61.
Found:	C, 47.16;	H, 5.25;	N, 12.44;	F, 9.79;	S, 4.48.

Example 7

[1S[2R*]]-N-[2-[2[[[1-((Hydroxyamino)iminomethyl))-
 4-phenyl]carbonyl]amino]methyl]-1-pyrrolidinyl]-1-
 (hydroxymethyl)-2-oxoethyl]-2-naphthalene
sulfonamide, trifluoroacetate salt




A.




To a stirred solution of 1-Boc-2-(methylazide)pyrrolidine (12.54 g, 55.5 mmol) in 10 mL of dry dichloromethane at 0 °C was added a solution of 4N HCl in dioxane (25.0 mL, 100 mmol). The solution was stirred at room temperature for 2.5 h and concentrated in vacuo to give a crude amine as an oil. To a stirred solution of this amine, N-Boc-L-serine (11.4 g, 55.5 mmol) and 1-hydroxybenzotriazole monohydrate (9.37 g, 55.5 mmol) in 240 mL of DMF was added in order N-methylmorpholine (18.3 mL, 167 mmol) and ethyl 3-(3-dimethyl amino)propyl carbodiimide hydrochloride (10.6 g, 55.5 mmol). The reaction solution was stirred at room temperature for 19 h and concentrated under pump vacuum at 45 °C. The residue was dissolved in 1 L of EtOAc and washed with 5% KHSO₄ solution (3x0.5 L), saturated NaHCO₃ solution (2x0.5 L) and brine (1x0.5 L). The EtOAc layer was dried (MgSO₄), filtered and concentrated in vacuo to give 14.4 g (83%) of title A amide.

B.




To a stirred solution of Part A amide (14.3 g, 45.9 mmol) in 20 mL of dry dichloromethane at 0 °C was added a solution of 4N HCl in dioxane (40.0 mL, 160 mmol). The solution was stirred at room temperature for 2 h and concentrated in vacuo to give a crude amine as an oil. To a stirred solution of this amine and triethylamine (15.4 mL, 110 mmol) in 100 mL of dry dichloromethane at 0 °C was added dropwise a solution of 2-naphthalenesulfonyl chloride (10.9 g, 48.2 mmol) in 60 mL of dry dichloromethane over 40 min. The reaction solution was stirred at 0 °C for 1 h and at room temperature for 2 h. The solution was diluted with 1 L of dichloromethane and washed with 1N HCl solution (3x0.5 L), saturated NaHCO₃ solution (2x0.5 L) and brine (1x0.5 L). The dichloromethane layer was dried (MgSO₄), filtered, concentrated in vacuo and triturated in EtOAc-hexane to give 11.5 g of Part B azide. The trituant was concentrated in vacuo and chromatographed on silica gel to give 1.4 g of title azide.

C.




To a stirred solution of Part B azide (11.2 g, 27.8 mmol) in 300 mL of EtOH and 600 mL of methanol was added 10% Pd/C (2.24 g). The atmosphere was replaced with hydrogen and the reaction mixture was stirred at room temperature for 17 h. The catalyst was filtered off, and rinsed with methanol, and the filtrate concentrated in vacuo to give 9.9 g (94%) of crude Part C amine.

D.



Part C amine (1.93 g, 5.15 mmol), 4-cyanobenzoic acid (757 mg, 5.15 mmol) and 1-hydroxybenzotriazole (869 mg, 6.44 mmol) were dissolved in DMF (30 mL) at RT. N-Methylmorpholine (1.1 mL, 10 mmol) was added dropwise followed by WSC (1.03g, 5.15 mmol). The reaction was stirred 20 hours at room temperature, the mixture diluted with ethyl acetate (75 mL) and KHSO₄ solution (60 mL), the layers separated and the aqueous layer was reextracted with ethyl acetate (75 mL). The combined organic layer was washed with sat'd. NaHCO₃ solution (50 mL) and 10% lithium chloride solution (2 x 25 mL), dried over magnesium sulfate and concentrated in vacuo. The crude product was chromatographed on silica gel, to provide Part D compound as a foam (2.01g, 78%).




Hydroxylamine hydrochloride (700 mg, 10 mmol) in methanol (10 mL) was treated with sodium carbonate (540 mg, 5 mmol). The mixture was stirred 15 minutes and filtered. The filtrate was added to the Part D cyano compound (1.0 mmol) and stirred at room temperature for eighteen hours. The solvent was removed *in vacuo*. The crude material was purified by preparative HPLC to provide title compound as a white solid (398 mg, 57%).

$[\alpha]_D = -36.9^\circ$ ($c = 0.7$, MeOH)

Analysis calcd for 1.15 TFA + 1.3 H ₂ O:					
	C, 48.97;	H, 4.76;	N, 10.09;	F, 9.44;	S, 4.62.
Found:	C, 49.24;	H, 4.79,;	N, 9.70;	F, 9.20;	S, 4.85.

Example 8

(S)-N-(2-((S)-1-(4-nitrophenyl)-2-oxoethyl)-4-nitro-L-phenylalanyl)-N-(1-phenylethyl)-L-allo-threoninamide



A. (R)-N²-[(1,1-Dimethylethoxy)carbonyl]-N-(1-methyl-2-phenylethyl)-L-allothreoninamide

To a solution of N-Boc-L-allothreonine (0.325 g, 1.48 mmol, 1.00 eq.) and 1-hydroxybenzotriazole hydrate (0.221 g, 1.64 mmol, 1.11 eq.) in dimethylformamide (5 mL) at 0°C was added 1-(3-

dimethylaminopropyl)-2-ethylcarbodiimide hydrochloride (WSC) (0.312 g, 1.63 mmol, 1.10 eq.). After 0.5 hr, a solution of (R) α -methylbenzylamine (0.20 mL, 1.55 mmol, 1.05 eq.) in dimethylformamide (3 mL) was added, followed by 4-methylmorpholine (0.16 mL, 1.46 mmol, 0.98 eq.). After 17 hr, the reaction mixture was poured into a brine/water solution (1:1) and extracted twice with ethyl acetate. The organic layers were combined and washed with aqueous 0.25 M potassium hydrogen sulfate, water, aqueous saturated sodium bicarbonate, water, dried over sodium sulfate, and the organic layer concentrated in vacuo to give title compound (0.448 g, 93.9%):

B. (R)-N²-[N-[(1,1-Dimethylethoxy)carbonyl]-4-nitro-L-phenylalanyl]-N-(1-methyl-2-phenylethyl)-L-allothreoninamide

To a solution of Part A compound (0.418 g, 1.29 mmol, 1.00 eq.) in dichloromethane (2.2 mL) under argon at 0 °C was added trifluoroacetic acid (1.5 mL, 19.5 mmol, 15.1 eq.). After 4.0 hr, trifluoroacetic acid (5 mL, 64.8 mmol, 5.44 eq.) was added. After 5 hr, the reaction mixture was concentrated in vacuo to give the crude TFA salt of Part A compound. To a solution of Boc-4-nitro-L-phenylalanine (0.441 g, 1.42 mmol, 1.10 eq.) and 1-hydroxybenzo-triazole hydrate (0.193 g, 1.43 mmol, 1.10 eq.) in dimethylformamide (5.0 mL) at 0 °C was added 1-(3-dimethylaminopropyl)-2-ethylcarbodiimide hydrochloride (0.273 g, 1.43 mmol, 1.10 eq.). After 0.5 hr, a solution of crude TFA salt of Part A compound (1.29 mmol, 1.00 eq.) in dimethylformamide (3.0 mL) was added, which was then followed by 4-methylmorpholine (0.5 mL, 4.55 mmol, 3.52 eq.). After 21 hr, the reaction mixture was poured into a brine/water solution (1:1) and extracted with ethyl acetate twice. The organic layers were combined and washed with aqueous 0.25 M potassium hydrogen sulfate, water, aqueous saturated sodium bicarbonate and water, successively. The organic layer was concentrated in vacuo to give title compound (0.651 g, 98.0%):

C. (R)-N²-[N-[(1,1-Dimethylethoxy)carbonyl]amino]-1-oxobutyl]-4-nitro-L-phenylalanyl]-N-(1-methyl-2-phenylethyl)-L-allothreoninamide

To a solution of Part B compound (0.6157 g, 1.20 mmol, 1.00 eq.) in dichloromethane (2.0 mL) under argon at 0 °C was added trifluoroacetic acid (1.4 mL, 18.2 mmol, 15.1 eq.). After 5.5 hr, the reaction mixture was concentrated in vacuo to give the crude TFA salt of Part B compound. To a solution of BocNH-(CH₂)₃CO₂H (0.268 g, 1.32 mmol, 1.10 eq.) and 1-hydroxybenzotriazole hydrate (0.179 g, 1.32 mmol, 1.10 eq.) in dimethylformamide (4.4 mL) at 0 °C was added 1-(3-dimethylaminopropyl)-2-ethylcarbodiimide hydrochloride (0.253 g, 1.32 mmol, 1.10 eq.). After 0.5 hr, a solution of crude TFA salt of Part B compound (1.20 mmol, 1.00 eq.) in dimethylformamide (2.4 mL) was added, which was then followed by N-methylmorpholine (0.30 mL, 2.73 mmol, 2.27 eq.). After 22 hr, the reaction mixture was poured into a brine/water solution (1:1) and extracted with ethyl acetate twice. The organic layers were combined and washed with aqueous 0.25 M potassium hydrogen sulfate, water, aqueous saturated sodium bicarbonate and water, successively. The organic layer was concentrated in vacuo and the crude solid was washed with diethyl ether to give title compound (0.710 g, 98.7%).


D. (S)-N<2-[N-[4-[(Hydroxyaminoiminomethyl)amino]-1-oxobutyl]-4-nitro-L-phenylalanyl]-N-(1-phenylethyl)-L-allo-threoninamide

To a solution of Part C compound (0.202 g, 0.337 mmol, 1.00 eq.) in dichloromethane (1.8 mL) at 0 °C under argon was added trifluoroacetic acid (1.2 mL). After 4.0 hr, the reaction mixture was concentrated in vacuo to give crude TFA salt of Part C compound. To a solution of crude TFA salt of Part C compound (0.337 mmol, 1.0 eq.) in MeOH (1.5 mL), was added NaOAc (0.138 g, 1.69 mmol) and BrCN (43 mg, 0.404 mmol). The reaction was stirred for 7 h. To this crude reaction mixture were added NH₂OH.HCl (351 mg, 5.06 mmol) and Na₂CO₃ (268 mg, 2.53 mmol). The reaction mixture was concentrated in vacuo and purified by preparative HPLC to yield title compound (0.045 g, 22%) as a white solid:


Anal. calcd. for C ₂₆ H ₃₅ N ₇ O ₇ • 1.10 TFA • 1.50 H ₂ O:				
Found:	C, 47.46; C, 47.70;	H, 5.58; H, 5.26;	N, 13.74; N, 13.37;	F, 8.78. F, 8.46.

Example 9


[2R-[1(2S*), 2 α , 4 β]]-1-[5-[Amino(hydroxyimino)methyl]-
 amino]-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-
 quinolylyl)sulfonyl]amino]-1-oxopentyl]-4-methyl-2-
piperidinecarboxylic acid, ethyl ester



A.




Ethyl-3-(3-dimethylamino)propyl carbodiimide hydrochloride (1.23 g, 6.42 mmol) was added to a solution of α -Boc- γ -CBZ-L-ornithine (2.35 g, 6.42 mmol) and 1-hydroxybenzotriazole (0.98 g, 6.42 mmol) in 26 mL of DMF. After 30 minutes, 2(R)-ethoxycarbonyl-4(R)-methylpiperidine




(1.00 g, 5.84 mmol) and 4-methyl-morpholine (0.64 mL, 5.8 mmol) were added, and the reaction was continued for 45 minutes. The reaction was quenched by the addition of 260 mL of 0.25 M KHSO₄ solution. The crude product was extracted with EtOAc (2 X 100 mL), the combined EtOAc layers were washed with 0.25 M KHSO₄ solution (3 X 50 mL), saturated KHCO₃ solution (3 X 50 mL), brine, dried (Na₂SO₄), and evaporated to yield 3.31 g of a colorless taffy. Flash chromatography on silica gel provided the title compound (2.60 g, 86%) as a colorless gum.

B.




Trifluoroacetic acid (33.0 mL) was added to Part A compound (2.49 g, 4.79 mmol) at 0 °C. The solution was stirred for 1 hour at room temperature. Trifluoroacetic acid was removed under vacuum with toluene. The residue was co-evaporated with ether and hexane to yield title compound (2.94 g, ca. 100%) as a gum.

C.



Triethylamine (0.73 mL, 5.3 mmol) followed by 3-methyl-8-chlorosulfonyl quinoline (1.27 g, 5.27 mmol) was added to a solution of Part B compound (2.56 g, 4.79 mmol) in 36.0 mL of CH₂Cl₂. After 3 hours, CH₂Cl₂ was removed *in vacuo*, the residue partitioned between EtOAc (30 mL) and 0.25 M KHSO₄ solution (20 mL), the EtOAc layer was washed with 0.25 M KHSO₄ solution (3 X 20 mL), saturated aqueous KHCO₃ solution (3 X 20 mL), brine, dried (Na₂SO₄), and evaporated under reduced pressure to yield 3.18 g of a gum. Flash chromatography on silica gel provided Part C title compound (2.23 g, 75%) as a glass.

D.




A solution of Part C compound (2.22 g, 3.55 mmol) in 33.0 mL of absolute EtOH with 2.22 g of palladium black was hydrogenated at 1 atmosphere for 3 days. The catalyst was removed by filtration, the filtrate concentrated and co-evaporated with ether and hexane to yield title compound (1.61 g, 92%) as a glass.

E.

5

10




15 Cyanogen bromide (0.34 g, 3.2 mmol) was added to a solution of Part D compound (1.33 g, 2.69 mmol) and NH_4OAc (0.46 g, 5.96 mmol) in 10.0 mL of CH_3OH . After 1 hour, an additional portion of cyanogen bromide was introduced (0.11 g, 1.07 mmol) and the reaction was continued for 24 hours. Methanol was removed under vacuum, and the Part E crude product was used for the next step without purification.

20

F.

25

30



35

A suspension of hydroxylamine hydrochloride (1.87 g, 26.9 mmol) and sodium carbonate (1.42 g, 13.5 mmol) in 34.0 mL of CH_3OH was stirred for 15 minutes. Insoluble material was removed by filtration and the filtrate was added directly to Part E compound. After 2 hours, the solvent was removed under reduced pressure, and the crude product purified by preparative HPLC to yield title compound (748 mg, 40%) as a colorless solid.

40

Anal., calcd for $\text{C}_{25}\text{H}_{40}\text{N}_6\text{O}_5\text{S} \cdot 1.15 \text{ CF}_3\text{COOH} \cdot 0.65 \text{ H}_2\text{O}$:					
	C, 47.14;	H, 6.15;	N, 12.08;	F, 9.42;	S, 4.61.
Found:	C, 47.16;	H, 5.96;	N, 11.74;	F, 9.48;	S, 4.60.

45


$[\alpha]_D = +84^\circ$ ($c = 0.5$, CH_3OH).

50


55

Example 10

N-[[[1-Amino(hydroxyimino)methyl]-4-piperidinyl]-
methyl]-1-[N-[carboxymethyl]-D-phenylalanyl]-L-
prolinamide




A. N-[(1,1-Dimethylethoxy)carbonyl]-4-
piperidinyl)methyl]-1-[N-[[[benzyloxy]-
carbonyl)methyl]-D-phenylalanyl]-L-
prolinamide




To a solution of Example 1, Part E compound (2.50 g, 5.05 mmol) in dry CH_2Cl_2 cooled at 0°C was added N, N-diisopropylethylamine (5.30 ml, 30.3 mmol), followed by benzyl 2-bromoacetate (1.12 ml, 7.07 mmol). The mixture was stirred at ambient temperature for 5.0 hrs, diluted with CH_2Cl_2 , washed with water, brine and dried over anhydrous Na_2SO_4 . Purification by flash chromatography afforded 2.21 g of Part A compound, as a white foam.

B. N-[(1,1-Dimethylethoxy)carbonyl]-4-piperidinylmethyl]-1-[N-[[benzyloxy]-carbonyl]methyl]-1-[N-benzyloxycarbonyl]-D-phenylalanyl]-L-prolinamide



To the solution of Part B compound (1.32 g, 2.17 mmol) in 5 ml of anhydrous DMF cooled at 0°C was added N, N-diisopropylethylamine (0.94 ml, 5.42 mmol), followed by benzyl chloroformate (0.46 ml, 3.25 mmol). The mixture was stirred at 0°C for 1.0 hr, diluted with CH₂Cl₂, washed with water, brine and dried over anhydrous Na₂SO₄. Purification by flash chromatography afforded 1.58 g (98%) of the Part B compound.

C. N-[[[1-Amino(hydroxyimino)methyl]-4-piperidinyl]methyl]-1-[N-[carboxymethyl]-D-phenylalanyl]-L-prolinamide



To the solution of Part B compound (1.58 g, 2.13 mmol) in 10 ml of dry CH₂Cl₂ at 0°C was added 10 ml of trifluoroacetic acid dropwise *via* an additional funnel. The mixture was stirred at 0°C for 1.0 hr and at room temperature for 1.0 hr. Concentration in vacuo followed by azeotropic evaporation with CH₂Cl₂-heptane gave 1.97 g of the TFA salt of the piperidinyl amine as a colorless oil. This material was used directly in the next reaction.

To the mixture of crude TFA salt of amine (1.97 g, 2.13 mmol) and anhydrous sodium acetate (1.05 g, 12.78 mmol) in 17 ml of anhydrous MeOH was added solid cyanogen bromide (338 mg, 3.20 mmol) portionwise. The mixture was stirred at room temperature for 2.0 hrs, concentrated, and the residue taken into CH₂Cl₂-water. The organic layer was separated and the aqueous layer was extracted once with CH₂Cl₂. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄ to give 1.26 g (91% crude) of the N-cyanamide intermediate as a white foam. This material was used directly in the next reaction.

To the mixture of N-cyanamide benzyl ester (987 mg, 1.48 mmol) in 4 ml of 1:1 THF-water was added LiOH·H₂O (153 mg, 1.78 mmol). The mixture was stirred at room temperature overnight. 0.1N HCl was added at 0°C until pH = 2.5, the mixture was extracted with EtOAc, and the combined organic extracts dried over anhydrous Na₂SO₄ to give 1.01 g of the free acid N-cyanamide as a white foam. This material was used directly in the next reaction.

A mixture of hydroxylamine hydrochloride (1.03 g, 14.8 mmol) and anhydrous sodium carbonate (784 mg, 7.4 mmol) in 3.7 ml of anhydrous MeOH was stirred vigorously for 1.0 hr. The solid was removed by filtration through a pad of Celite, the filtrate was added to 1.01 g (1.48 mmol) of crude N-cyanamide, and the reaction mixture was stirred overnight at room temperature. Concentration *in vacuo* afforded 1.42 g of
5 crude hydroxyguanidine which was taken into a mixture of MeOH (10 ml) and glacial acetic acid (6 ml). To this mixture was added 250 mg of 20% Pd(OH)₂, and the mixture was hydrogenated at one atmosphere for 5.0 hrs. The palladium catalyst was removed by filtration, the filtrate concentrated and the product purified to give 220 mg of the title compound.

Following the procedures of Examples 1 to 10, the following examples of compounds of the invention
10 may be prepared.

15

20

25

30

35


40

45

50

55

TABLE



Example	R ⁵	R ⁴	R ³	R ²	Q	R ¹
11	C ₂ H ₅ SO ₂ -	CH ₂ OCH ₂ Ph(s)	H	CH ₃		NH ₂
12	C ₆ H ₅ SO ₂ -	H	OH	H		OH

Example

No.

50

55

R1

୩

8

 \mathbb{R}^2




R³

2

R^s

 OC_2H_5 NH_2

ННЧН **Э**



20

25

30

35


40

45

0


CH 3

ОСНЗ

$$-\text{CH}_2\text{C}_6\text{H}_5(\text{R})$$


13


•

 CH_3
$$-\text{CH}_2\text{C}_6\text{H}_5(\text{R})$$


14

1

五

$$-\text{CH}_2\text{CH}_2\text{CONH}_2(\text{B})$$


15

5

10

15

20

25

30






35

40

45

50

55

Example No.	R ⁵	R ⁴	R ³	R ²	R	Q	R ¹
16	C ₆ H ₅ -CO-	-CH ₂ CH ₂ CONH ₂ (R)	H	CH ₃	1		NO ₂
17		-CH(OH)CH ₃ (S-Thr)	-CHCH ₂ CH ₂ CH- 0		0		CN
18		CH(OH)CH ₃ (S-alloThr)	CH ₃	H	1		OH

Example No.	R ⁵	R ⁴	R ³	R ²	R	Q	R ¹
19			SCH ₃	CH ₃	1		OCH ₃
20		-CH ₂ CH ₂ CO ₂ H(R)	H	CH ₃	0		NH ₂
21	H	CH ₂ OCH ₂ Ph(R)	H	H	1		N(CH ₃) ₂

5

10

15

20

25

30

35

40

45

50

55

Example
No.

R¹

R²

R³

R⁴

R⁵

NO₂

1

H

H

CH₂CH₂Ph(s)

22


OH

1



H

H


-CH₂-



23



TABLE



Example
No.

R¹

Q

R

R²R³R⁴R⁵NH₂

1

CH₃

H

C₂H₅O₂C-CH₂-CH₂OCH₂Ph(S)

24

OH

0

H

OH

H

CH₃OO₂C-CH₂-

25

Example No.	R ⁵	R ⁴	R ³	R ²	R	Q	R ¹
26	CH ₃ O ₂ C-(CH ₂) ₂ -	-CH ₂ C ₆ H ₅ (R)	OCH ₃	CH ₃	O		OC ₂ H ₅
27		-CH ₂ C ₆ H ₅ (R)	CH ₃	H	O		NH ₂
28		-CH ₂ CH ₂ CONH ₂ (S)	H	H	1		NHCH ₃

Example	No.	R ⁵	R ⁶	R ³	R ²	R	Q	R ¹
29		$\text{C}_2\text{H}_5\text{O}_2\text{C}-\text{C}_6\text{H}_4-(\text{CH}_2)_2-$	$-\text{CH}_2\text{CH}_2\text{CONH}_2(\text{R})$	H	CH_3	1		NO_2
30		$\text{C}_2\text{H}_5-\text{O}_2\text{C}-\text{CH}_2-$	$-\text{CH}(\text{OH})\text{CH}_3(\text{S-Thr})$	$-\text{CHCH}_2\text{CH}_2\text{CH}-$	0			CN
31		$\text{C}_6\text{H}_5\text{O}_2\text{C}-\text{C}_6\text{H}_4-\text{CH}_2-$	$\text{CH}(\text{OH})\text{CH}_3(\text{S-alloThr})$	CH_3	H	1		OH

Exemple	R ⁵	R ⁴	R ³	R ²	R ¹
32			CH ₃	CH ₃	
33		-CH ₂ CH ₂ CO ₂ H (R)	H	CH ₃	NH ₂
34		CH ₂ CCH ₂ Ph (R)	H	H	N(CH ₃) ₂

5

10

15

20

25

30

35

40

45

50

55

Example

No.

R¹

Q

R

R²

R³

R⁴

R⁵

NO₂

1

H

H

CH₂CH₂Pb(S)

C₆H₅CH₂O₂C-(CH₂)₃-



35

OH



1

H


H









36




5
10
15
20
25
30
35
40
45
50
55



Example	R ⁵	R ⁹	a	R ³	R ²	R ¹
37	CBZ	CO ₂ CH ₃	0	H	CH ₃	CN
38	CH ₃ O ₂ C-CH ₂ -	CO ₂ C ₂ H ₅	1	OH	H	OH
39	C ₆ H ₅ CO	CO ₂ C ₃ H ₇	2	OCH ₃	CH ₃	NH ₂
40		H	3	CH ₃	CH ₃	CN
41		H	0	H	CH ₃	OH


Example No.	R ⁵	R ⁹	z	R ³	R ²	R	R ¹
42	C ₆ H ₅ -CH ₂ CO-	H	1	H	CH ₃	H	OH
43		CO ₂ CH ₃	2	-CHCH ₂ CH ₂ CH-	0	C ₃ H ₇	NH ₂
44		CO ₂ C ₃ H ₅	3	CH ₃	H	CH ₃	N(CH ₃) ₂
45		H	0	SCH ₃	CH ₃	H	NO ₂
46		CO ₂ C ₃ H ₇	1	H	CH ₃	H	OH

Example	No.	R ^{5'}	R ^{4'}	R ^{6'}	R	R ¹	R
47		$ \begin{array}{c} \text{C}_6\text{H}_5 \\ \\ \text{CH}_2 \\ \\ \text{C} \begin{array}{l} \nearrow \text{H} \\ \searrow \text{CH}_3 \end{array} \end{array} $	CH ₂ OH (S)		CH ₃	CN	
48		$ \begin{array}{c} \text{CH}_3 \\ \\ (\text{CH}_2)_2 \\ \\ \text{C} \begin{array}{l} \nearrow \text{H} \\ \searrow \text{CO}_2\text{H} \end{array} \end{array} $	H	-(CH ₂) ₂ CO ₂ H	H	OH	
49		$ \begin{array}{c} \text{C}_6\text{H}_5 \\ \\ \text{CH}_2 \\ \\ \text{C} \begin{array}{l} \nearrow \text{H} \\ \searrow \text{CONHCH}_3 \end{array} \end{array} $	-CH ₂ C ₆ H ₅ (R)		C ₆ H ₅	NH ₂	C ₂ H ₅

Example	No.	R ⁵	R ⁴	R ³	R	R ¹	P
50			CH ₂ OCH ₂ Ph(R)		H	CN	1
51			CH ₂ CH ₂ Ph(S)	CO ₂ H	C ₂ H ₅	OH	1
52					H	OCH ₃	2

Claims



1. A compound having the structure




wherein Z is a thrombin inhibitor substructure containing residues binding at the distal and proximal sites; and

R¹ is cyano, hydroxyl, alkoxy, amino, aminoalkyl or nitro;
including all stereoisomers thereof and pharmaceutically acceptable salts thereof.

2. The compound as defined in Claim 1 wherein Z is



or



wherein n is 0, 1 or 2;


G is an amido, sulfur, or oxygen linking moiety;

R² and R³ are independently hydrogen, lower alkyl, cycloalkyl, aryl, hydroxy, alkoxy, oxo, thioketal,

thioalkyl, thioaryl, amino or alkylamino; or R² and R³ together with the carbons to which they are attached form a cycloalkyl, aryl or heteroaryl ring;

R⁴ is hydrogen, hydroxyalkyl, hydroxy(alkyl)alkyl, aminoalkyl, alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amidoalkyl, arylalkoxyalkyl or an amino acid side chain, either protected or unprotected;


R⁵ is




where R⁶ is alkyl, aryl, arylalkyl, cycloheteroalkyl, heteroaryl, quinolinyl or tetrahydroquinolinyl; or

R⁵ is

(2) hydrogen,




-CO₂R⁷, CONHR⁷, R⁷O₂C-alkyl-,



wherein R⁷ is lower alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroaryl; and R⁷' is hydrogen, lower alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroalkyl;

R⁵ is



where z is 0, 1 or 2;

R¹⁰ is H, alkyl, cycloalkyl, aryl, cycloheteroalkyl or heteroaryl;

R¹¹ is H, alkyl, CO₂R^c or CONR^aR^b, wherein R^c is H or alkyl and R^a and R^b are independently selected from H, alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl.

R⁴ is an amino acid side chain;

t is 2, 3, 4 or 5;

R is H or lower alkyl;

R⁸ is -(CH₂)_y-R¹² wherein y is 0, 1 or 2 and R¹² is cycloalkyl, heteroaryl, CO₂H, CONR^aR^b or aryl optionally substituted with NO₂, OH, alkoxy, acyloxy,




halogen, alkyl, aryl, CO₂alkyl, CONHalkyl, alkylthio, arylthio, NHalkyl or NHcycloalkyl;

s is 2, 3 or 4 ; and

R⁹ is H or CO₂R¹⁶ wherein R¹⁶ is H or alkyl.

3. A compound having the formula




wherein n is 0, 1 or 2;

R¹ is cyano, hydroxyl, alkoxy, amino, aminoalkyl or nitro;

R² and R³ are independently hydrogen, lower alkyl, cycloalkyl, aryl, hydroxy, alkoxy, oxo, thioether, thioalkyl, thioaryl, amino or alkylamino; or R² and R³ together with the carbons to which they are attached form a cycloalkyl, aryl or heteroaryl ring;

R⁴ is hydrogen, hydroxyalkyl, hydroxy(alkyl)alkyl, aminoalkyl, alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amidoalkyl, arylalkoxyalkyl or an amino acid side chain, either protected or unprotected;


R⁵ is




where R⁶ is alkyl, aryl, arylalkyl, cycloheteroalkyl, heteroaryl, quinoliny or tetrahydroquinoliny; or

R⁵ is

(2) hydrogen,




-CO₂R⁷, CONHR⁷, R⁷O₂C-alkyl-,



wherein R⁷ is lower alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroaryl; and R^{7'} is hydrogen, lower alkyl, aryl, arylalkyl, cyclohetero-alkyl or heteroalkyl;

G is



15 wherein m is 0, 1, 2, 3 or 4, and p is 0, 1 or 2, and either N or A is connected to



A is aryl or cycloalkyl, or A is an azacycloalkyl ring of 3 to 7 carbons in the ring or an azacycloheteroalkyl ring of 4 to 6 carbons in the ring each of the structure



35 where X is CH₂, O or S;

q is 0, 1, 2, 3 or 4,

provided that q is 0, 1, 2, 3 or 4 if X is CH₂ and

q is 2, 3 or 4 if x is O or S;

Y¹ and Y² are independently H, lower alkyl, halo or oxo;

40 provided that where X is O or S, A is azacycloheteroalkyl, then there must be at least a 2-carbon chain between X and any N atom in the ring or outside the ring;


X¹ is NHCO, S, SO, SO₂ or O, or a pharmaceutically acceptable salt thereof.

4. A compound having the formula


45

50

55



wherein R¹ is cyano, hydroxyl, alkoxy, amino, aminoalkyl or nitro;
R⁵ is



where z is 0, 1 or 2;

R¹⁰ is H, alkyl, cycloalkyl, aryl, cycloheteroalkyl or heteroaryl;

R¹¹ is H, alkyl, CO₂R^c or CONR^aR^b, wherein R^c is H or alkyl and R^a and R^b are independently selected from H, alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl.

R⁴ is an amino acid side chain;

t is 2, 3, 4 or 5;


R is H or lower alkyl;

R⁸ is -(CH₂)_y-R¹² wherein y is 0, 1 or 2 and R¹² is cycloalkyl, heteroaryl, CO₂H, CONR^aR^b or aryl optionally substituted with NO₂, OH, alkoxy, acyloxy,



halogen, alkyl, aryl, CO₂alkyl, CONHalkyl, alkylthio, arylthio, NHalkyl or NHcycloalkyl; or a pharmaceutically acceptable salt thereof.


5. A compound having the formula



wherein n is 0, 1 or 2;

R² and R³ are independently hydrogen, lower alkyl, cycloalkyl aryl, hydroxy, alkoxy, oxo, thioether, thioalkyl, thioaryl, amino or alkylamino; or R² and R³ together with the carbons to which they are attached form a cycloalkyl, aryl or heteroaryl ring;

R⁵ is




where R⁶ is alkyl, aryl, arylalkyl, cycloheteroalkyl, heteroaryl, quinolinyl or tetrahydroquinolinyl; or

R⁵ is

(2) hydrogen,



-CO₂R⁷, CONHR⁷, R⁷O₂C-alkyl-,



wherein R⁷ is lower alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroaryl; and R⁷' is hydrogen, lower alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroalkyl;

R is H or lower alkyl;

s is 2, 3 or 4 ;

R⁹ is H or CO₂R¹⁶ wherein R¹⁶ is H or alkyl;

and R¹ is cyano, hydroxyl, alkoxy, amino, aminoalkyl or nitro; or a pharmaceutically acceptable salt thereof.


6. The compound as defined in Claim 3 having the formula

5

10

15

20




7. The compound as defined in Claim 3 having the formula

25

30

35

40




8. The compound as defined in Claim 3 having the formula


45

50

55




9. The compound as defined in Claim 3 having the formula




10. The compound as defined in Claim 1 wherein R¹ is OH, CN, NHR, or Oalkyl.

11. The compound as defined in Claim 3 wherein R⁵ is



or HO₂Calkyl-,

R⁴ is arylalkyl or hydroxyalkyl, n is 0, R² and R³ are each H, G is




15

and R¹ is OH, CN, NHR, or Oalkyl.

12. The compound as defined in Claim 4 wherein
R⁵ is


20



25


R⁴ is

30



35

R⁸ is




40

t is 3 and R¹ is OH.

13. The compound as defined in Claim 5 wherein R⁵ is

45

50



55

R² and R³ are each H, R⁹ is CO₂alkyl, n is 1, s is 3, R is H and R¹ is OH.

14. The compound as defined in Claim 1 wherein Z is



or



wherein n is 0, 1 or 2;

G is an amido, sulfur, or oxygen linking moiety;

40

R⁴ is hydrogen, hydroxyalkyl, hydroxy(alkyl)alkyl, aminoalkyl, alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amidoalkyl, arylalkoxyalkyl or an amino acid side chain, either protected or unprotected;

45



where R⁶ is alkyl, aryl, arylalkyl, cycloheteroalkyl, heteroaryl, quinolinyl or tetrahydroquinolinyl; or

\mathbb{R}^5 is


55



5

$\text{---CO}_2\text{R}^7$, CONHR^7 , wherein R^7 is lower alkyl, aryl, arylalkyl, cycloheteroalkyl or heteroaryl;
 $\text{R}^{5'}$ is

10



15

where z is 0, 1 or 2;

R^{10} is H, alkyl, cycloalkyl, aryl, cycloheteroalkyl or heteroaryl;

20

R^{11} is H, alkyl, CO_2R^c or CONR^aR^b , wherein R^c is H or alkyl and R^a and R^b are independently selected from H, alkyl, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl.

R^d is an amino acid side chain;

t is 2, 3, 4 or 5;

R is H or lower alkyl;

25

R^8 is $\text{---}(\text{CH}_2)_y\text{---R}^{12}$ wherein y is 0, 1 or 2 and R^{12} is cycloalkyl, heteroaryl, CO_2H , CONR^aR^b or aryl optionally substituted with NO_2 , OH, alkoxy, acyloxy,



30


halogen, alkyl, aryl, CO_2 alkyl, CONH alkyl, alkylthio, arylthio, NH alkyl or NH cycloalkyl;

s is 2, 3 or 4 ; and

R^9 is H or CO_2R^{16} wherein R^{16} is H or alkyl.

35 15. The compound as defined in Claim 13 having the formula

40




45

wherein G is

50

55



15 wherein m is 0, 1, 2, 3 or 4, and p is 0, 1 or 2, and either N or A is connected to



A is aryl or cycloalkyl, or A is an azacycloalkyl ring of 3 to 7 carbons in the ring or an azacycloheteroalkyl ring of 4 to 6 carbons in the ring each of the structure



35 where X is CH₂, O or S;
 q is 0, 1, 2, 3 or 4,
 provided that q is 0, 1, 2, 3 or 4 if X is CH₂
 and
 q is 2, 3 or 4 if X is O or S;
 40 Y¹ and Y² are independently H, lower alkyl, halo or oxo;
 provided that where X is O or S, A is azacycloheteroalkyl, then there must be at least a 2-carbon
 chain between X and any N atom in the ring or outside the ring;
 X¹ is NHCO, S, SO, SO₂ or O, or a
 pharmaceutically acceptable salt thereof.

- 45 16. The compound as defined in Claim 1 which is
- N-[[1-[(hydroxyamino)iminomethyl]-4-piperidinyl]methyl]-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalanyl]-L-prolinamide or salts thereof including its trifluoroacetate salt;
- 50 N-[[1-[(cyanoamino)iminomethyl]-4-piperidinyl]methyl]-1-[N-[(phenylmethyl)sulfonyl]-D-phenylalanyl]-L-prolinamide or salts thereof;
- N-[[1-[(hydroxyamino)iminomethyl]-4-piperidinyl]methyl]-1-[N-[(methylsulfonyl)-D-phenylalanyl]-L-prolinamide or salts thereof;
- N-[[1-[(cyanoamino)iminomethyl]-4-piperidinyl]methyl]-1-[N-[(methylsulfonyl)-D-phenylalanyl]-L-prolinamide or salts thereof;
- 55 N-[[1-[(methoxyamino)iminomethyl]-4-piperidinyl]methyl]-1-[N-[(methylsulfonyl)-D-phenylalanyl]-L-prolinamide or salts thereof;
- [1S(2R*(3R*))]-N-[2-2[[[1-[(hydroxyamino)iminomethyl]-3-piperidinyl]carbonyl]amino]methyl]-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalene sulfonamide or salts thereof;

[1S[2R*]]-N-[2-[2-[[[1-((hydroxyamino)iminomethyl))-4-phenyl]carbonyl]amino]methyl]-1-pyrrolidinyl]-1-(hydroxymethyl)-2-oxoethyl]-2-naphthalene sulfonamide or salts thereof;

(R)-N²-[N-[4-[(aminoiminoethyl)amino]-1-oxobutyl]-4-nitro-L-phenylalanyl]-N-(1-methyl-2-phenylethyl)-L-allothreoninamide or salts thereof;

[2R-[1(2S*),2 α ,4 β]]-1-[5-[amino(hydroxyimino)methyl]amino]-2-[[1,2,3,4-tetrahydro-3-methyl-8-quinolylyl)sulfonyl]amino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid, esters thereof, or the ethyl ester or salts thereof; or

N-[[[1-amino(hydroxyimino)methyl]-4-piperidinyl]methyl]-1-[N-[carboxymethyl]-D-phenylalanyl]-L-prolinamide or salts thereof.

17. The compounds as defined in Claim 1 which is N-[[[1-amino(hydroxyimino)methyl]-4-piperidinyl]-methyl]-1-[N-[carboxymethyl]-D-phenylalanyl]-L-prolinamide or salts thereof.

18. Use of a compound as defined in Claim 1 for manufacturing a medicament for inhibiting or preventing formation of blood clots.

19. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier thereof.